Efficacy and Safety of Adsorptive Granulocyte and Monocyte Apheresis in Elderly and Pregnant Patients With Ulcerative Colitis. Issue 3 (26th May 2019)

• Record Type: Journal Article
• Authors: Yanagisawa, Kazuki; Murakami, Minoru; Kondo, Yuya; Oguma, Shun; Kobayashi, Shun; Miyasaka, Hiroshi; Shinohara, Tomoaki; Tomori, Akihisa; Nakano, Yui; Furuhata, Shunichi; Ikezoe, Masaya
• Other Names: Ueda Yasunori guestEditor.
• Is Part Of: Therapeutic apheresis and dialysis. Volume 23:Issue 3(2019)
• Page Start: 217
• Page End: 223
• Publication Date: 2019-05-26
• Subjects: Adsorptive granulocyte and monocyte apheresis -- Elderly patient -- Lactating mother -- Ulcerative colitis; Hemapheresis -- Periodicals; Dialysis -- Periodicals; Blood Component Removal -- Periodicals; Renal Dialysis -- Periodicals; Hémaphérèse -- Périodiques; Dialyse -- Périodiques; Sang -- Collecte et conservation -- Périodiques; 616
• DOI: 10.1111/1744-9987.12818
• Languages: English
• ISSNs: 1744-9979

Abstract

Abstract: In patients with active ulcerative colitis (UC), adsorptive granulocyte/monocyte apheresis (GMA) is expected to promote remission. We conducted a retrospective cohort study to evaluate the efficacy and safety of GMA in patients with active UC. Twenty‐one UC patients including five pregnant or lactating mothers and four elderly patients (aged >60 years) received up to 10 GMA sessions. UC severity was evaluated at baseline and after GMA therapy according to Lichtiger's Clinical Activity Index (CAI). We defined clinical remission as CAI ≤4. Overall, the median CAI score after GMA therapy had decreased from 9 to 4 ( P < 0.001). The clinical remission rate was 62%, but in the elderly and pregnant or lactating mothers, the remission rates were 100% and 60%, respectively. No severe adverse effects were seen in this study. Our results may support GMA as an effective and safe treatment for active UC patients, including elderly patients and pregnant cases.